{
    "clinical_study": {
        "@rank": "153122", 
        "arm_group": {
            "arm_group_label": "bitopertin-Midazolam", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This will be a single-center, open-label, inpatient/outpatient, fixed-sequence study\n      examining the effect of multiple doses of bitopertin on single doses of Midazolam in healthy\n      volunteers.\n\n      A single oral dose on Midazolam (7.5 mg) will be administered on Day 1 after an overnight\n      fast. Daily oral doses of bitopertin will be given under fed conditions from Days 2-13 and\n      after fasting on Day 14. Oral doses of bitopertin and Midazolam (7.5 mg) will be\n      co-administered on Day 15, after an overnight fast.\n\n      Pharmacokinetics will be assessed throughout. Total time on treatment is expected to be 15\n      days."
        }, 
        "brief_title": "A Study Exmining the Effect of Multiple Doses of Bitopertin on the Single Dose Pharmacokinetics of Midazolam in Healthy Volunteers.", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteer", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female volunteers, 18 to 65 years of age, inclusive.\n\n          -  A BMI between 18 to 30 kg/m2, inclusive.\n\n          -  Healthy as determined by the Investigator on the basis of medical/surgical history,\n             physical examination, clinical laboratory test results, vital signs and 12-lead\n             electrocardiogram (ECG)\n\n          -  Female participants must use effective contraception as defined by the protocol and\n             cannot be pregnant or breastfeeding\n\n          -  Non-smoker or smoker of fewer than 10 cigarettes per day\n\n          -  Must be able to refrain from smoking during the in-patient stay\n\n        Exclusion Criteria:\n\n          -  Personal or family history of congenital long QT syndrome or family history of sudden\n             death\n\n          -  Any major illness within the 4 weeks prior to dosing or any acute disease state\n             within 7 days prior to study start\n\n          -  History of alcoholism, drug abuse or addiction within the last year prior to study\n             start, or suspicion of drug abuse/addiction or alcohol use prior to study start\n\n          -  Current alcohol consumption averaging more than 24 g of alcohol per day\n\n          -  Any significant allergic reactions against any drug, or multiple allergies in the\n             judgment of the Investigator"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 18, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02019290", 
            "org_study_id": "BP29245"
        }, 
        "intervention": [
            {
                "arm_group_label": "bitopertin-Midazolam", 
                "description": "An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.", 
                "intervention_name": "bitopertin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "bitopertin-Midazolam", 
                "description": "Single oral doses will be given on Days 1 and 15, after an overnight fast.", 
                "intervention_name": "Midazolam", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Midazolam"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Rennes", 
                    "country": "France", 
                    "zip": "35042"
                }
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "1", 
        "official_title": "A SINGLE CENTER, OPEN LABEL, FIXED SEQUENCE STUDY TO INVESTIGATE THE EFFECT OF MULTIPLE DOSE BITOPERTIN ON SINGLE DOSE PHARMACOKINETICS OF MIDAZOLAM IN HEALTHY VOLUNTEERS", 
        "overall_contact": {
            "email": "global.rochegenentechtrials@roche.com", 
            "last_name": "Reference Study ID Number: BP29245 www.roche.com/about_roche/roche_worldwide.htm", 
            "phone": "888-662-6728 (U.S. Only)"
        }, 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "France: ANSM (Agence National de Securite du Medicament)"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in plasma area under the concentration-time curve (AUC) of midazolam after bitopertin administration", 
            "safety_issue": "No", 
            "time_frame": "Days 1 and 15"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02019290"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in 1'-hydroxymidazolam plasma AUC after bitopertin administration", 
                "safety_issue": "No", 
                "time_frame": "Days 1 and 15"
            }, 
            {
                "measure": "Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "Approximately 76 days"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}